Pipeline

Life sciences are radically improving the chances of treatment, even for disease that have yet to find therapeutic answers. Thanks to new knowledge of biotechnology, ever-increasing computing power and the advancement of artificial intelligence, we will be able to respond to patients' needs even faster.

Clinical Pipeline

With our research and development pipeline, we target some of the highest-needing therapeutic areas.

Platform - Asset	Indication	Phase 1 Phase 2 Phase 3 Post-Market
Ophtha - NGF	Front-of-the-eye: Neurotrophic Keratitis
Ophtha - NGF	Front-of-the-eye: Sjogren-related Dry Eye
Ophtha - NGF Intravitreal	Back-of-the-eye
NETosis - Reparixin	Community Acquired Pneumonia (CAP)
NETosis - Reparixin	Acute Respiratory Distress Syndrome (ARDS)
NETosis - Ladarixin	Type 1 Diabetes – Early Onset
NETosis - Ladarixin	Type 1 Diabetes – Insulin resistant
Primary Care - KLS-Gaba	Low-back pain

Ophtha - NGF

Indication: Front-of-the-eye: Neurotrophic Keratitis

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

Ophtha - NGF

Indication: Front-of-the-eye: Sjogren-related Dry Eye

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

Ophtha - NGF Intravitreal

Indication: Back-of-the-eye

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

NETosis - Reparixin

Indication: Community Acquired Pneumonia (CAP)

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

NETosis - Reparixin

Indication: Acute Respiratory Distress Syndrome (ARDS)

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

NETosis - Ladarixin

Indication: Type 1 Diabetes – Early Onset

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

NETosis - Ladarixin

Indication: Type 1 Diabetes – Insulin resistant

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

Primary Care - KLS-Gaba

Indication: Low-back pain

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

Latest Publications

Sars-Cov-2

Pain & Antiflammation

Oncology

Ophthalmology

Preclinical Programs

Relevance of Spike/Estrogen Receptor-α interaction for endothelial-based coagulopathy induced by SARS-CoV-2

19/05/2023

Authors: Silvia Stella Barbieri, Franca Cattani, Leonardo Sandrini, Magda Maria Grillo, Alessandra Amendola, Carmen Valente, Carmine Talarico, Daniela Iaconis, Gabriele Turacchio, Miriam Lucariello, Lucia Lione, Erika Salvatori, Patrizia Amadio, Gloria Garoffolo, Mariano Maffei, Francesca Galli, Andrea Rosario Beccari, Giuseppe Sberna, Emanuele Marra, Marica Zoppi, Michael Michaelides, Giuseppe Roscilli, Luigi Aurisicchio, Riccardo Bertini, Marcello Allegretti, Maurizio Pesce

Published in:

Nature

Sars-CoV-2

Find out more

NGF for brain injuries: a groundbreaking trial completed in Italy

10/05/2023

Authors: Antonietta Curatola, Benedetta Graglia, Giuseppe Granata, Giorgio Conti, Lavinia Capossela, Luigi Manni, Serena Ferretti, Daniela Di Giuda, Domenico Marco Romeo, Maria Lucia Calcagni, Marzia Soligo, Enrico Castelli, Marco Piastra, Flavio Mantelli, Giacomo Della Marca, Susanna Staccioli, Tiziana Romeo, Marcello Pani, Fabrizio Cocciolillo, Aldo Mancino, Antonio Gatto, Antonio Chiaretti

Published in:

Biology Direct

Pain & Antiflammation

Find out more

Ketoprofen, lysine and gabapentin co-crystal magnifies synergistic efficacy and tolerability of the constituent drugs: Pre-clinical evidences towards an innovative therapeutic approach for neuroinflammatory pain

09/05/2023

Authors: Andrea Aramini, Gianluca Bianchini, Samuele Lillini, Mara Tomassetti, Niccolò Pacchiarotti, Daniele Canestrari, Pasquale Cocchiaro, Rubina Novelli, Maria Concetta Dragani, Ferdinando Palmerio, Simone Mattioli, Simone Bordignon, Michele d’Angelo, Vanessa Castelli, Francesco d’Egidio, Sabatino Maione, Livio Luongo, Serena Boccella, Annamaria Cimini, Laura Brandolini, Marcello Allegretti

Published in:

Science Direct

Pain & Antiflammation

Find out more

Marcello Allegretti,

Chief Scientific Officer